SEC Filing Summary: Genesis Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Genesis Biopharma, Inc. (not IOVANCE Biotherapeutics, Inc.) on July 6, 2012, reporting events occurring on June 30, 2012. The company is a Nevada corporation headquartered in Los Angeles, California.
Key Financial Metrics
The filing discloses the following specific financial data:
- Debt Instrument: Secured Promissory Notes totaling $1.1 million.
- Issuance Period: May and June 2012.
- Original Maturity: June 30, 2012.
- Revised Maturity: September 30, 2012.
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, or overall liquidity positions beyond the specific note extension.
Material Changes
The primary material change reported is the entry into a Maturity Date Extension agreement with all eleven purchasers of the $1.1 million in Secured Promissory Notes. The maturity date was extended by three months from June 30, 2012, to September 30, 2012. All other terms and conditions of the Notes remain unchanged.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks beyond the immediate debt restructuring. The extension of the maturity date implies a need for additional time to arrange repayment or refinancing, though the filing does not explicitly state the company's liquidity status or repayment strategy.
Key Facts for Investor Verification
- Verify the company name discrepancy: The filing is for Genesis Biopharma, Inc., not IOVANCE Biotherapeutics, Inc.
- Confirm the status of the $1.1 million debt obligation as of the new September 30, 2012, maturity date.
- Review subsequent filings to determine if the notes were repaid, refinanced, or converted.
- Assess the company's overall liquidity position given the necessity of extending short-term secured debt.